12 09, 2018

Cassipa Approved by FDA for Opioid Dependence

By | 2018-09-12T15:28:07+00:00 September 12th, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

A new dosage strength of buprenorphine and naloxone sublingual film was approved recently by the Food and Drug Administration. Cassipa sublingual film, made by Teva Pharmaceuticals, is a 16 mg/4 mg dosage of buprenorphine and naloxone for the maintenance treatment of opioid dependence. Buprenorphine and naloxone sublingual film also is [...]

23 08, 2018

How a Distant Epidemic Came Home to Roost: One Man’s Opioid Addiction

By | 2018-09-12T14:58:24+00:00 August 23rd, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

A front page New York Times story read, “Every year, thousands of people addicted to opioids show up at hospital emergency rooms in withdrawal so agonizing it leaves them moaning and agonizing on the floor.” The article then goes on to quote a heroin addict. I would have stopped reading [...]

9 08, 2018

Seven-Year Analysis on Benzodiazepine Prescribing for Children, Adolescents, and Young Adults Showed Marked Increase

By | 2018-08-09T08:01:59+00:00 August 9th, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Conclusions The overall increase in prevalence rates of BZD dispensations during the study period and the unexpectedly high proportion of individuals who were prescribed a BZD on a long-term basis at a young age indicate a lack of congruence with international and national guidelines. These findings highlight the need for [...]

7 08, 2018

An Approach to the Pharmacotherapy of Neuroleptic Malignant Syndrome

By | 2018-08-07T12:30:37+00:00 August 7th, 2018|Articles In Press|0 Comments

By Roland van Rensburg and Eric H. Decloedt Abstract Neuroleptic malignant syndrome is a rare, idiosyncratic emergency associated with exposure to dopamine antagonists, commonly antipsychotic drugs. The typical clinical picture consists of altered consciousness, muscular rigidity, fever, and autonomic instability. While the condition has generally been well described, the pathophysiology is still [...]

2 08, 2018

Alzheimer’s Agent, BAN2401, Shows Promise; Trial Design Hits Snag

By | 2018-08-02T07:56:18+00:00 August 2nd, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

A monoclonal antibody,BAN2401, that targets soluble amyloid-beta oligomers, slowed cognitive decline by up to 47% while clearing brain amyloid in 81% of patients with mild cognitive impairment and very mild Alzheimer’s disease, according to phase 2 study results. A joint venture with Esai and Biogen, BAN2401, is among the most promising [...]

29 06, 2018

Akathisia Induced by Abrupt Withdrawal of Risperidone: A Case Report

By | 2018-08-02T12:16:42+00:00 June 29th, 2018|Articles In Press|0 Comments

By Gangaparameswari Soundarrajan, Bharti Chogtu Magazine, Vybhav Krishna, Avinash Kamath G, and Manisha murugesan Abstract Akathisia is a common movement disorder that occurs as a consequence of antipsychotic therapy. However, its occurrence secondary to risperidone withdrawal has been reported rarely. Reporting of such rare adverse event gains profound importance because changing the antipsychotics is very [...]

29 06, 2018

Exercise as a Treatment for Schizophrenia: a Review

By | 2018-08-02T12:16:42+00:00 June 29th, 2018|Articles In Press|0 Comments

By Steven J. Girdler, Jamie E. Confino and Mary E. Woesner Abstract Schizophrenia is a mental disorder that is characterized by progressive cognitive impairment in areas of attention, working memory, and executive functioning. Although no clear etiology of schizophrenia has been discovered, many factors have been identified that contribute to the development [...]

29 06, 2018

Bipolar Medication, Lamictal, Linked with Serious Immune System Reaction

By | 2018-06-29T07:28:14+00:00 June 29th, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

The Food and Drug Administration has issued a warning that the seizure and bipolar medication Lamictal (lamotrigine) can cause a rare but potentially life-threatening immune response. This life-threatening immune response, known as hemophagocytic lymphohistiocytosis (HLH), causes an uncontrolled immune response and can present as a persistent fever greater than 101° F. [...]

8 06, 2018

Effects of a depression-focused internet intervention in slot machine gamblers: A randomized controlled trial

By | 2018-06-08T16:28:40+00:00 June 8th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|0 Comments

By Lara Bücker , Julia Bierbrodt, Iver Hand, Charlotte Wittekind, and Steffen Moritz Background Problematic and pathological gambling have been linked to depression. Despite a high demand for treatment and negative financial consequences, only a small fraction of problematic and pathological gamblers seek professional help. The existing treatment gap could be narrowed by providing [...]

8 06, 2018

Alzheimer’s Therapy Elenbecestat Reduces Brain Amyloid Levels, Trial Shows, but Decline of Clinical Symptoms Still a Question

By | 2018-06-08T08:10:58+00:00 June 8th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|0 Comments

Treatment with the investigational compound elenbecestat reduced brain amyloid beta levels and was safe and well-tolerated, according to Phase 2 clinical trial results. The presence of amyloid beta plaques is a major characteristic of the brains of Alzheimer’s disease patients. Amyloid beta is produced through the work of a key enzyme called [...]